Synthesis and discovery of macrocyclic polyoxygenated bis-7-azaindolylmaleimides as a novel series of potent and highly selective glycogen synthase kinase-3β inhibitors

被引:84
作者
Kuo, GH [1 ]
Prouty, C [1 ]
DeAngelis, A [1 ]
Shen, L [1 ]
O'Neill, DJ [1 ]
Shah, C [1 ]
Connolly, PJ [1 ]
Murray, WV [1 ]
Conway, BR [1 ]
Cheung, P [1 ]
Westover, L [1 ]
Xu, JZ [1 ]
Look, RA [1 ]
Demarest, KT [1 ]
Emanuel, S [1 ]
Middleton, SA [1 ]
Jolliffe, L [1 ]
Beavers, MP [1 ]
Chen, X [1 ]
机构
[1] Johnson & Johnson Pharmaceut Res & Dev LLC, Drug Discovery Div, Raritan, NJ 08869 USA
关键词
D O I
10.1021/jm030115o
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Attempts to design the macrocyclic maleimides as selective protein kinase C γ inhibitors led to the unexpected discovery of a novel series of potent and highly selective glycogen synthase kinase-3β (GSK-3β) inhibitors. Palladium-catalyzed cross-coupling reactions were used to synthesize the key intermediates 17 and 22 that resulted in the synthesis of novel macrocycles. All three macrocyclic series (bisindolyl-, mixed 7-azaindoleindolyl-, and bis-7-azaindolylmaleimides) were found to have submicromolar inhibitory potency at GSK-3β with various degrees of selectivity toward other protein kinases. To gain the inhibitory potency at GSK-3β, the ring sizes of these macrocycles may play a major role. To achieve the selectivity at GSK-3β, the additional nitrogen atoms in the indole rings may contribute to a significant degree. Overall, the bis-7-azaindolylmaleimides 28 and 29 exhibited little or no inhibitions to a panel of 50 protein kinases. Compound 29 almost behaved as a GSK-3β specific inhibitor. Both 28 and 29 displayed good potency in GS cell-based assay. Molecular docking studies were conducted in an attempt to rationalize the GSK-3β selectivity of azaindolylmaleimides.
引用
收藏
页码:4021 / 4031
页数:11
相关论文
共 50 条
[1]  
[Anonymous], SYBYL VERS 6 9
[2]  
Bray A. M., 1998, [No title captured], Patent No. [9816528, WO9816528]
[3]   Inhibition of tau phosphorylation: a new therapeutic strategy for the treatment of Alzheimer's disease and other neurodegenerative disorders [J].
Castro, A ;
Martinez, A .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2000, 10 (10) :1519-1527
[4]   AN INTERNAL COORDINATE MONTE-CARLO METHOD FOR SEARCHING CONFORMATIONAL SPACE [J].
CHANG, G ;
GUIDA, WC ;
STILL, WC .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1989, 111 (12) :4379-4386
[5]   Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription [J].
Coghlan, MP ;
Culbert, AA ;
Cross, DAE ;
Corcoran, SL ;
Yates, JW ;
Pearce, NJ ;
Rausch, OL ;
Murphy, GJ ;
Carter, PS ;
Cox, LR ;
Mills, D ;
Brown, MJ ;
Haigh, D ;
Ward, RW ;
Smith, DG ;
Murray, KJ ;
Reith, AD ;
Holder, JC .
CHEMISTRY & BIOLOGY, 2000, 7 (10) :793-803
[6]   Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death [J].
Cross, DAE ;
Culbert, AA ;
Chalmers, KA ;
Facci, L ;
Skaper, SD ;
Reith, AD .
JOURNAL OF NEUROCHEMISTRY, 2001, 77 (01) :94-102
[7]   Crystal structure of glycogen synthase kinase 3β:: Structural basis for phosphate-primed substrate specificity and autoinhibition [J].
Dajani, R ;
Fraser, E ;
Roe, SM ;
Young, N ;
Good, V ;
Dale, TC ;
Pearl, LH .
CELL, 2001, 105 (06) :721-732
[8]   Specificity and mechanism of action of some commonly used protein kinase inhibitors [J].
Davies, SP ;
Reddy, H ;
Caivano, M ;
Cohen, P .
BIOCHEMICAL JOURNAL, 2000, 351 (351) :95-105
[9]   PROTEIN-KINASE-C - A QUESTION OF SPECIFICITY [J].
DEKKER, LV ;
PARKER, PJ .
TRENDS IN BIOCHEMICAL SCIENCES, 1994, 19 (02) :73-77
[10]   Inhibitors of glycogen synthase kinase-3: future therapy for unmet medical needs? [J].
Dorronsoro, I ;
Castro, A ;
Martinez, A .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2002, 12 (10) :1527-1536